MeitY Startup Hub onboards MergerDomo to strengthen start-up ecosystem in India
Posted By - Investment Banker
A pharmaceutical client is looking out for acquiring a GMP / MHRA approved/certified Formulation plant having a capacity of approx 200-250 MT per month and an API plant having capacity of producing volume building API’s ( paracetamol, ibuprofen, Metformin) of around 300 – 500 MT per month anywhere in India. The firm has established world-class manufacturing facilities by leveraging state-of-the-art technology, incorporating best practices and adhering to stringent regulatory compliance. The Plants are approved by prestigious US FDA, UK MHRA, Australian TGA and other foreign health authorities. R&D capabilities include dossier development, chemical synthesis, process optimization, formulation development, analytical development.
 Deal Size
|
INR 100 - 200 Cr |
| Special Requirement: Tablets and Capsules capacity | |
Industry
Pharmaceuticals
Sub-Industry
Integrated
Target Location
12, 9, 14, 15, 33, 16, 1, 17, 6, 4, 18, 19, 20, 10, 21, 7, 2, 22, 23, 24, 25, 26, 5, 3, 31, 30, 29, 28, 13, 8, 27
Type
General & Beta Lactum
Product
paracetamol, ibuprofen, Metformin
Export
Yes
Formulation type
Oral Solids, Liquids, Parenteral
Type
Branded
Therapeutic Area
Chronic, Acute
Funding Sources
Cash,Fresh Debt
Synergies Sought
Manufacturing Strengths (Production/Operations)
Complete Buyout
Industry: Pharmaceuticals
Sub-Industry: Bulk Drug manufacturing
Division
Division`s Buyers/Customers
Division`s Plant Location
If you are interested in connecting with business, please send an Expression of Interest and receive Information Memo to take this opportunity further
EXPRESS INTEREST MARK FAVOURITE
